Open Access

Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma

  • Authors:
    • Jian Liu
    • Yan Li
    • Xiaoqin Zhu
    • Qing Li
    • Xiaohong Liang
    • Jun Xie
    • Song Hu
    • Wanda Peng
    • Chong Li
  • View Affiliations

  • Published online on: April 3, 2019     https://doi.org/10.3892/ol.2019.10211
  • Pages: 4877-4890
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemokines are a family of small cytokines, which are signalling proteins secreted by cells. The principal role of chemokines is to serve as chemoattractants to guide the migration of their target cells. Chemokine C‑X3‑C motif ligand 1 (CX3CL1) is a protein‑coding gene of fractalkine, which serves as a ligand for chemokine C‑X3‑C motif receptor 1 (CX3CR1) and integrins. However, the roles of CX3CL1 in different pathological types of lung cancer remain poorly understood. The present study aimed to investigate the potential clinical and biological function of CX3CL1 mRNA expression in patients with lung cancer. In the present study, lung cancer data obtained from the Gene Expression Omnibus database and The Cancer Genome Atlas were downloaded and analysed, and the results demonstrated that an increased CX3CL1 mRNA expression in tumour tissues from lung adenocarcinoma (LUAD) was associated with improved overall survival. However, no significant association was identified between CX3CL1 expression and the prognosis of lung squamous cell carcinoma (LUSC). Furthermore, the genes whose expression levels were correlated with CX3CL1 expression were subjected to enrichment analysis, and the results for the LUAD data demonstrated that the most significant biological processes included ‘positive regulation of cell adhesion’, ‘leukocyte cell‑cell adhesion’, ‘leukocyte migration’ and ‘T cell activation’, whereas, the important highly ranked pathways included ‘cell adhesion molecules (CAMs)’, ‘leukocyte transendothelial migration’ and ‘natural killer cell‑mediated cytotoxicity’. However, in the patients with LUSC, the genes that were highly correlated with CX3CL1 were not enriched for any biological processes or signalling pathways. Based on the data of the present study, it was hypothesised that CX3CL1 may serve as a prognostic marker for LUAD.

References

1 

Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Borsig L, Wolf MJ, Roblek M, Lorentzen A and Heikenwalder M: Inflammatory chemokines and metastasis-Tracing the accessory. Oncogene. 33:3217–3224. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Liu W, Jiang L, Bian C, Liang Y, Xing R, Yishakea M and Dong J: Role of CX3CL1 in diseases. Arch Immunol Ther Exp. 64:371–383. 2016. View Article : Google Scholar

4 

Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA, Vath J, Gosselin M, Ma J, Dussault B, et al: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 387:611–617. 1997. View Article : Google Scholar : PubMed/NCBI

5 

Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature. 385:640–644. 1997. View Article : Google Scholar : PubMed/NCBI

6 

Julia V, Staumont-Salle D and Dombrowicz D: Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic diseases. Med Sci (Paris). 32:260–266. 2016.(Article in French). View Article : Google Scholar : PubMed/NCBI

7 

Thomas S and Baumgart DC: Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 20:1–18. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T, Imai H, Yoshie O, Bloom ET, Domae N and Umehara H: Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. 164:4055–4062. 2000. View Article : Google Scholar : PubMed/NCBI

9 

Gu X, Tang XD, Gu SY, Yang SQ, Zhou PJ and Tan JM: Expression of fractalkine and its receptor in acute cardiac allografts rejection. Zhonghua wai ke za zhi. 41:139–142. 2003.(In Chinese). PubMed/NCBI

10 

Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R and Tanaka T: Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 15:1775–1782. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H and Mori M: The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 26:41–47. 2005.PubMed/NCBI

12 

Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadière C, Prévot S, Machelon V and Balabanian K: Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One. 6:e215462011. View Article : Google Scholar : PubMed/NCBI

13 

Kim M, Rooper L, Xie J, Kajdacsy-Balla AA and Barbolina MV: Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res. 10:11–24. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Li F, Wang Z, Liu Y and Li J: Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol Rep. 24:669–675. 2010.PubMed/NCBI

15 

Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, et al: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 17:945–951. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O and Fatatis A: The chemokine receptor CX(3)CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res. 13:R912011. View Article : Google Scholar : PubMed/NCBI

17 

Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 5:186ra1662013. View Article : Google Scholar

19 

Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et al: Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, Mao J, White MA, et al: A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 19:1577–1586. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff Finder: A comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI

25 

Yao X, Qi L, Chen X, Du J, Zhang Z and Liu S: Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma. Urol Oncol. 32:162–170. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Johnson LA and Jackson DG: The chemokine CX3CL1 promotes trafficking of dendritic cells through inflamed lymphatics. J Cell Sci. 126:5259–5270. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O and Imai T: Fractalkine in vascular biology: From basic research to clinical disease. Arterioscler Thromb Vasc Biol. 24:34–40. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T and Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 188:1413–1419. 1998. View Article : Google Scholar : PubMed/NCBI

29 

Park MH, Lee JS and Yoon JH: High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol. 106:386–392. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: Potential role in prostate cancer bone tropism. Cancer Res. 68:1715–1722. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI

32 

Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, et al: The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 68:9060–9069. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Zhou B, Xu H, Ni K, Ni X and Shen J: Expression of chemokine XCL2 and CX3CL1 in lung cancer. Med Sci Monit. 22:1560–1565. 2016. View Article : Google Scholar : PubMed/NCBI

34 

Locatelli M, Boiocchi L, Ferrero S, Martinelli Boneschi F, Zavanone M, Pesce S, Allavena P, Maria Gaini S, Bello L and Mantovani A: Human glioma tumors express high levels of the chemokine receptor CX3CR1. Eur Cytokine Netw. 21:27–33. 2010.PubMed/NCBI

35 

Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, et al: Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer. 46:3383–3392. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Sciume G, Soriani A, Piccoli M, Frati L, Santoni A and Bernardini G: CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1. Neuro Oncol. 12:701–710. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, Luci C, Breittmayer V, Anjuère F, Schmid-Alliana A and Schmid-Antomarchi H: Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut. 56:365–372. 2007. View Article : Google Scholar : PubMed/NCBI

38 

Xin H, Kanehira M, Mizuguchi H, Hayakawa T, Kikuchi T, Nukiwa T and Saijo Y: Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells. 25:1618–1626. 2007. View Article : Google Scholar : PubMed/NCBI

39 

Erreni M, Siddiqui I, Marelli G, Grizzi F, Bianchi P, Morone D, Marchesi F, Celesti G, Pesce S, Doni A, et al: The fractalkine-receptor axis improves human colorectal cancer prognosis by limiting tumor metastatic dissemination. J Immunol. 196:902–914. 2016. View Article : Google Scholar : PubMed/NCBI

40 

Matsubara T, Ono T, Yamanoi A, Tachibana M and Nagasue N: Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol. 95:241–249. 2007. View Article : Google Scholar : PubMed/NCBI

41 

Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P and Mantovani A: Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol. 224:39–44. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, J., Li, Y., Zhu, X., Li, Q., Liang, X., Xie, J. ... Li, C. (2019). Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma. Oncology Letters, 17, 4877-4890. https://doi.org/10.3892/ol.2019.10211
MLA
Liu, J., Li, Y., Zhu, X., Li, Q., Liang, X., Xie, J., Hu, S., Peng, W., Li, C."Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma". Oncology Letters 17.6 (2019): 4877-4890.
Chicago
Liu, J., Li, Y., Zhu, X., Li, Q., Liang, X., Xie, J., Hu, S., Peng, W., Li, C."Increased CX3CL1 mRNA expression level is a positive prognostic factor in patients with lung adenocarcinoma". Oncology Letters 17, no. 6 (2019): 4877-4890. https://doi.org/10.3892/ol.2019.10211